Cibenzoline attenuates upregulation of Kv1.5 channel gene expression by experimental paroxysmal atrial fibrillation

International Heart Journal

Volumn 46, Issue 2, 2005, Pages 279-288

  Yamashita, Takeshi ^a   Sekiguchi, Akiko ^a   Iwasaki, Yu Ki ^a   Sagara, Kouichi ^a   Hatano, Seiji ^a   Iinuma, Hiroyuki ^a   Aizawa, Tadanori ^a   Fu, Long Tai ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Atrial fibrillation; Cibenzoline; Kv1.5

Indexed keywords

ANTIARRHYTHMIC AGENT; CIBENZOLINE; ION CHANNEL; MESSENGER RNA; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.5; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; KCNA5 PROTEIN, RAT; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION REGULATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HYPOTHESIS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT; REFRACTORY PERIOD; UPREGULATION; ANIMAL; ARTIFICIAL HEART PACEMAKER; BIOSYNTHESIS; ELECTROPHYSIOLOGY; GENETICS; HEART ATRIUM; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; NERVE CONDUCTION; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROPHYSIOLOGY; HEART ATRIA; HEART CONDUCTION SYSTEM; IMIDAZOLES; KV1.5 POTASSIUM CHANNEL; PACEMAKER, ARTIFICIAL; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, SPRAGUE-DAWLEY; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; RNA, MESSENGER; UP-REGULATION;

EID: 23044478969     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.279     Document Type: Article

References (25)

1. Go AS, Hylek EM, Phillips KA, er al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
2. Wijffels MC, Kirchhof CJ, Dorland F, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
3. Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000; 87: 440-7. (Review)
4. + channels in rat atrium: electrical remodeling in paroxysmal atrial tachycardia. Circulation 2000; 101: 2007-14.
5. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythinic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003; 107: 1440-6.
6. Bosch RF, Zeng Y, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44: 121-31.
7. Komatsu T, Nakamura S, Suzuki O, et al. Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients. J Cardiol 2003; 41: 191-8. (Japanese)
8. Komatsu T. Nakamura S, Kimura M, et al. Efficacy of cibenzoline in the termination and long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset J Cardiol 2001; 37: 75-82. (Japanese)
9. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
10. + channels? Circ Res 1995; 77: 361-9.
11. Wallenstein S, Zucker C, Fleiss J. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1-9.
12. Niwa R, Honjo H, Kodama I, Maruyama K, Toyama J. Na channel blocking effects of cibenzoline on guineapig ventricular cells. Eur J Pharmacol 1998; 352: 317-27.
13. Masse C, Cazes M, Sassine A. Effects of cibenzoline, a novel antiarrhythmic drug, on action potential and transmembrane currents in frog atrial muscle. Arch Int Pharmacodyn Ther 1984; 269: 219-35.
14. Sato T, Wu B, Kiyosue T, Arita M. Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 167-73.
15. 2+ inward current by the class I antiarrhythmic agent, cibenzoline. Br J Pharmacol 1986; 87: 705-11.
16. 2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. Gen Pharmacol 1991; 22: 87-91.
17. + current of guinea-pig ventricular myocytes. J Mol Cell Cardiol 1996; 28: 893-903.
18. + channels in guinea-pig ventricular cells. Br J Pharmacol 1993; 108: 549-56.
19. Wu SN, Nakajima T, Yamashita T, et al. Molecular mechanism of ciberizoline-induced anticholinergic action in single atrial myocytes: comparison with effect of disopyramide. J Cardiovasc Pharmacol 1994; 23: 618-23.
20. Millar JS, Vaughan Williams EM. Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol 1982; 75:469-78.
21. Millar JS, Vaughan Williams EM. Pharmacological mapping of regional effects in the rabbit heart of some new antiarrhythmic drugs. Br J Pharmacol 1983; 79: 701-9.
22. Dangman KH. Cardiac effects of cibenzoline. J Cardiovasc Pharmacol 1984; 6: 300-11.
23. Satoh H, Ishii M, Hashirnoto IC Effect of cibenzoline, a class I antiarrhythmic drug, on action potential in canine ventricular muscle. Jpn J Pharmacol 1987; 44: 113-9.
24. Kotake H, Matsuoka S, Ogino K, Takami T, Hasegawa J, Mashiba H. Electrophysiological study of cibenzoline in voltage-clamped rabbit sinoatrial node preparations. J Pharmacol Exp Ther 1987; 241: 982-6.
25. Mori Y, Matsubara H, Folco E, Siegel A, Koren G. The transcription of a mammalian voltage-gated potassium channel is regulated by cAMP in a cell-specific manner. J Biol Chem 1993; 268: 26482-93.